New Link Found in Lung Cancer
Researchers studied a type of protein modification called myristoylation in non-small cell lung cancer cells. They found that certain proteins, including GLIPR2, play a role in a process called ferroptosis, which can kill cancer cells. The researchers used a new method to identify these proteins and understand their function.
Why it matters: This finding could lead to new therapeutic strategies for non-small cell lung cancer.
This is an early stage, preclinical study.
View source →Hormone Therapy for Breast Cancer
This trial is studying hormone therapy with or without chemotherapy for women who have had surgery for node-negative breast cancer. The trial is currently active but not recruiting new participants. Researchers are still gathering information.
Why it matters: This trial matters because it may help determine the best treatment approach for women with certain types of breast cancer.
The trial is no longer recruiting new participants.
View source →Propofol Enhances Cancer Treatment
Researchers studied how propofol affects non-small cell lung cancer cells. They found that propofol makes these cells more sensitive to a common chemotherapy drug. This happened through a process that involves modifying a protein called PARP-1.
Why it matters: This finding matters because it could help scientists understand how to make chemotherapy more effective for patients with non-small cell lung cancer.
This is an early study using animal models and lab experiments, and more research is needed to confirm these results in humans.
View source →Combining Treatments for Lung Cancer
Researchers studied combining cetuximab with KRAS G12C inhibitors in lung cancer cells. They found that this combination enhanced the effect of one inhibitor, fulzerasib, in certain cells. The combination also changed the expression of various proteins in these cells.
Why it matters: This finding matters because it could help tailor treatments for patients with a specific type of lung cancer.
This is an early, preclinical study using cell lines and animal models, and its results may not translate to humans.
View source →Trial Tests New Combo for Advanced Breast Cancer
This trial is studying a new combination of treatments for advanced triple-negative breast cancer. It's adding an anti-cancer drug called ZEN-3694 and a PD-1 inhibitor to standard chemotherapy. The trial is currently recruiting participants.
Why it matters: This trial matters because it may help find new and more effective treatments for advanced triple-negative breast cancer.
The trial is in its early stage and currently recruiting participants, so limited data is available.
View source →Nivolumab and Ipilimumab Trial
This trial is studying the use of nivolumab and ipilimumab in treating patients with rare tumors. The trial is currently active but not recruiting new patients. Researchers are collecting data to see how well these treatments work.
Why it matters: This trial matters because it may help find new treatments for people with rare types of cancer.
The trial is currently not recruiting new patients and is in an early stage of research.
View source →